Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the ...

Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

This out-of-favor drug maker is taking the steps needed to ensure it not only survives but thrives over the long term.

Elsewhere, the busy earnings season continues with reports due from several notable companies such as Advanced Micro Devices, Palantir (NASDAQ:PLTR), Robinhood, Super Micro Computer, Qualcomm, ARM ...

In the latest close session, Pfizer (PFE) was down 1.09% at $24.50. This move lagged the S&P 500's daily gain of 0.23%. Meanwhile, the Dow experienced a rise of 0.34%, and the technology-dominated ...

The first full week of November delivers a broad and high-impact earnings lineup across semiconductors, cloud software, AI, ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $30.0 for Pfizer during the past quarter. Looking at the volume ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Eli Lilly reported strong earnings and raised guidance. Read more on what could be next for this biotech giant.

The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee ...

Pfizer has an analyst consensus of Hold, with a price target consensus of $28.60, a 15.46% upside from current levels. In a report released on October 22, Bank of America Securities also reiterated a ...